Clinical Trial Update: Single Ascending Dose Study of SRA-444 in Healthy Subjects [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 single ascending dose study of SRA-444 in healthy subjects. The sponsor Wyeth is now a wholly owned subsidiary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SRA-444

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED